TY - JOUR
T1 - The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways
AU - Turbyville, Thomas J.
AU - Wijeratne, E. M.Kithsiri
AU - Whitesell, Luke
AU - Gunatilaka, A. A.Leslie
PY - 2005/10
Y1 - 2005/10
N2 - Tumors are dependent on cellular stress responses, in particular the heat shock response, for survival in their hypoxic, acidotic, and nutrient-deprived microenvironments. Using cell-based reporter assays, we have identified terrecyclic acid A (TCA) from Aspergillus terreus, a fungus inhabiting the rhizosphere of Opuntia versicolor of the Sonoran desert, as a small-molecule inducer of the heat shock response that shows anticancer activity. Further characterization suggested that TCA also affects oxidative and inflammatory cellular stress response pathways. The presence of an α-methylene ketone moiety suggested that TCA may form adducts with sulfhydryl groups of proteins. Reaction with labile intracellular cysteines was supported by our finding that the glutathione precursor N-acetyl-cysteine protected tumor cells from the cytotoxic effects of TCA whereas the glutathione-depleting agent buthionine sulfoximine enhanced its activity. Related sesquiterpenes have been shown to increase levels of reactive oxygen species (ROS) and to inhibit nuclear factor κB (NF-κB) transcriptional activity. To assess whether TCA could have similar activities, we used a ROS-sensitive dye and flow cytometry to show that TCA does indeed increase ROS levels in 3LL cells. When tested in cells carrying NF-κB reporter constructs, TCA also exhibited concentration-dependent inhibition of cytokine-induced NF-κB transcriptional activity. These findings suggest that TCA modulates multiple stress pathways - the oxidative, heat shock, and inflammatory responses - in tumor cells that promote their survival. Small-molecule natural products such as TCA may serve as useful probes for understanding the relationships between these pathways, potentially providing leads for the design of novel and effective anti-cancer drugs.
AB - Tumors are dependent on cellular stress responses, in particular the heat shock response, for survival in their hypoxic, acidotic, and nutrient-deprived microenvironments. Using cell-based reporter assays, we have identified terrecyclic acid A (TCA) from Aspergillus terreus, a fungus inhabiting the rhizosphere of Opuntia versicolor of the Sonoran desert, as a small-molecule inducer of the heat shock response that shows anticancer activity. Further characterization suggested that TCA also affects oxidative and inflammatory cellular stress response pathways. The presence of an α-methylene ketone moiety suggested that TCA may form adducts with sulfhydryl groups of proteins. Reaction with labile intracellular cysteines was supported by our finding that the glutathione precursor N-acetyl-cysteine protected tumor cells from the cytotoxic effects of TCA whereas the glutathione-depleting agent buthionine sulfoximine enhanced its activity. Related sesquiterpenes have been shown to increase levels of reactive oxygen species (ROS) and to inhibit nuclear factor κB (NF-κB) transcriptional activity. To assess whether TCA could have similar activities, we used a ROS-sensitive dye and flow cytometry to show that TCA does indeed increase ROS levels in 3LL cells. When tested in cells carrying NF-κB reporter constructs, TCA also exhibited concentration-dependent inhibition of cytokine-induced NF-κB transcriptional activity. These findings suggest that TCA modulates multiple stress pathways - the oxidative, heat shock, and inflammatory responses - in tumor cells that promote their survival. Small-molecule natural products such as TCA may serve as useful probes for understanding the relationships between these pathways, potentially providing leads for the design of novel and effective anti-cancer drugs.
UR - http://www.scopus.com/inward/record.url?scp=27644509738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27644509738&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-05-0050
DO - 10.1158/1535-7163.MCT-05-0050
M3 - Article
C2 - 16227407
AN - SCOPUS:27644509738
SN - 1535-7163
VL - 4
SP - 1569
EP - 1576
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 10
ER -